RVMD vs. BNTX, TEVA, BGNE, GMAB, VTRS, ITCI, MRNA, SMMT, RDY, and CTLT
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry.
Revolution Medicines vs.
Revolution Medicines (NASDAQ:RVMD) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.
94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 8.0% of Revolution Medicines shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, BioNTech had 3 more articles in the media than Revolution Medicines. MarketBeat recorded 10 mentions for BioNTech and 7 mentions for Revolution Medicines. BioNTech's average media sentiment score of 0.29 beat Revolution Medicines' score of 0.26 indicating that BioNTech is being referred to more favorably in the news media.
Revolution Medicines has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500.
Revolution Medicines presently has a consensus target price of $66.25, indicating a potential upside of 64.43%. BioNTech has a consensus target price of $142.72, indicating a potential upside of 27.50%. Given Revolution Medicines' stronger consensus rating and higher possible upside, equities research analysts plainly believe Revolution Medicines is more favorable than BioNTech.
Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -15.16%. BioNTech's return on equity of -2.35% beat Revolution Medicines' return on equity.
BioNTech received 49 more outperform votes than Revolution Medicines when rated by MarketBeat users. However, 75.83% of users gave Revolution Medicines an outperform vote while only 46.05% of users gave BioNTech an outperform vote.
BioNTech has higher revenue and earnings than Revolution Medicines. BioNTech is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Summary
BioNTech beats Revolution Medicines on 10 of the 18 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:RVMD) was last updated on 1/21/2025 by MarketBeat.com Staff
Free RVMD Stock Alerts